Nandrolone Decanoate Injection

(Intramuscular Injection 250mg/ml)


Each 1 ml. of Nandrolone Decanoate contains 250 mg. in Oily base. Ethyl oleate quantity sufficient and Benzyl alcohol.

Pharmacological action

Nandrolone Decanoate has both androgenic and anabolic properties when administered parentally Nandrolone Decanoate is gradually released from the intramuscular depot and subsequently hydrolyzed into Nandrolone.


1)Nandrolone Decanoate is indicated in the treatment of anemia associated with renal insufficiency. 2)Certain cases of disseminated breast cancer in post-menopausal women and women without ovaries. 3)Osteoporosis due to androgen deficiency in hypogonadal males.


-Contraindicated in infant, pregnancy & lactating mothers.
-Carcinoma of prostate and carcinoma of male breast.
-Contraindicated in nephrosis or the nephrotic phase of nephritis, cardiac and renal failure, hypercalcaemia, oedema, jaundice, liver disease with impaired bilirubin excretion, testicular and hepatic carcinoma. Nandrolone Decanoate is not intended for use in female patients other than those with disseminated breast cancer.

Dosage and directions for use

Nandrolone Decanoate injections should be administered intramuscularly, preferably deep into the gluteal muscle. When using Nandrolone Decanoate injections, an adequate iron intake is required for maximum response. If any solid matters separate out, it should be redissolved by warming before use.


Females: intramuscular, 50 to 100 mg given every one to four week. Males: intramuscular, 50 to 250 mg given every one to four week. Note: When given at three to four week intervals, therapy may be continued for up to 12 weeks. If necessary, cycle maybe repeated if second course is preceded by a four-week rest period.


Children up to 2 years of age: Dosage might be determined by the physician. Children 2 to 13 years of age: Intramuscular, 25 to 50 mg every three to four weeks.

Side effects

Oedema, cholestatic jaundice, hepatic carcinoma, Gynaecomastia, Precocious puberty & shortening of stature due to early closure of epiphysis. Rashes, cramp dyspepsia. Virilisation which appears in sensitive women as hoarseness, acne, hirsutism, and increased libido and menstrual irregularities.


Patients with the following conditions should be monitored:
-In cardiac failure, renal dysfunction, hypertension, epilepsy or migraine (or a history of these conditions), since anabolic steroids may induce salt and fluid retention.
-Diabetes: Anabolic steroids may improve the glucose tolerance and decrease the need for insulin or other antidiabetic drugs.
-Incomplete statural growth: Anabolic steroids in high dosages may accelerate epiphyseal closure
-Skeletal metastases: Anabolic steroids may induce hypercalcemia and hypercalciuria in these patients.
-Liver dysfunction.
-If signs of virilization develop, treatment should be discontinued.

Drug interactions

-Potentiates corticosteroids
-Potentiates oral anticoagulants thereby enhancing bleeding tendency.
-Liver-enzyme-inducing agents may reduce the effects of Nandrolone Decanoate by enhancing its metabolism in the liver
-Reducing efficacy of cyclophosphamide in advanced breast cancer.


Overdoses are not frequent as physician or other expert administers it. Acute intramuscular toxicity of nandrolone is very low.


Not to be refrigerated. Store in a cool dry place below 30°C. Protect from light. Keep out of reach of children.


10 ml. vial is packed in a carton tray. Each carton tray includes 10 ml. vial and information leaflet.